Ireland
--:--IST
Starting soon Phase 1/2

A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

NCT07694765 · tracked via the Priya Life Science Australia tracker
Phase
Phase 1/2
Started
2026-07-15
Last updated
2026-07-10

Condition(s) studied

Malignant Tumors

Investigational drug(s) / intervention(s)

LM-364 for injection →Tislelizumab →

LM-364 for injection: Q3W, Intravenous Drip

Tislelizumab: Q3W, Intravenous Drip

Study summary

For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors.

For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Participants who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure. 2. Participants must be ≥18 years or the legal age of consent at the time of signing the ICF. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Life expectancy ≥ 3 months. 5. Adequate organ and bone marrow function as defined by protocol. 6. Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study. Exclusion Criteria: 1. Participant in any other clinical trial within 28 days prior to 1st dosing of LM-364. 2. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v6.0. 3. Participants with uncontrolled tumour-related pain. 4. Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-364. 5. Participants who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-364. 6. Participants who have severe cardiovascular disease. 7. Participants who have uncontrolled or severe illness. 8. Participants who have a history of immunodeficiency disease. 9. Participants with a known history of autoimmune disease. 10. Participants who have other active malignancies which are likely to require the treatment. 11. Child-bearing potential female who have positive results in pregnancy test or are lactating. 12. Participants who have psychiatric illness or disorders that may preclude study compliance. 13. Participants who is judged as not eligible to participate in this study by the investigator.

Primary outcome measure(s)

  • Incidence of dose-limiting toxicity (DLT) — 78 weeks
    Phase I
  • Incidence of Treatment-Emergent Adverse Events (AEs) — 78 weeks
    Phase I
  • Incidence of serious adverse events (SAEs) — 78 weeks
    Phase I
  • Temperature (Celsius) — 78 weeks
    Phase I
  • Pulse in BPM(Beat per Minute) — 78 weeks
    Phase I
  • Blood Pressure in mmHg — 78 weeks
    Phase I
  • Weight in Kg — 78 weeks
    Phase I
  • Height in centimeters — 78 weeks
    Phase I
  • Blood Routine examination -> Complete Blood Count — 78 weeks
    Phase I
  • Urine Routine examination ->Urinalysis — 78 weeks
    Phase I
  • Blood Biochemistry test -> Electrolytes and Metabolic Parameters — 78 weeks
    Phase I
  • Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), — 78 weeks
    Phase I
  • Pregnancy test — 78 weeks
    Phase I
  • Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) — 78 weeks
    Phase I
  • Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentage — 78 weeks
    Phase I
  • 12-lead electrocardiogram (ECG) in HR — 78 weeks
    Phase I
  • 12-lead electrocardiogram (ECG) in RR — 78 weeks
    Phase I
  • 12-lead electrocardiogram (ECG) in QRS — 78 weeks
    Phase I
  • 12-lead electrocardiogram (ECG) in QT — 78 weeks
    Phase I
  • 12-lead electrocardiogram (ECG) in QTcF — 78 weeks
    Phase I
  • ECOG(Eastern Cooperative Oncology Group) score — 78 weeks
    Phase I
  • Objective Response Rate (ORR) — 130 weeks
    Phase II

Trial sites (3)

FacilityCityRegionStatus
Macquarie University North Ryde New South Wales
Cancer Care Wollongong Hospital Wollongong New South Wales
Icon Cancer Centre South Brisbane Brisbane Queensland
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07694765 on ClinicalTrials.gov ↗ ← All trials in Australia